News

November 14, 2019December 20, 2019

FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma ... Read more

November 12, 2019

Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL

News

Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people with ... Read more

November 8, 2019

Advanced Follicular Lymphoma Patients Show Positive Overall Response to Umbralisib in Phase 2 Trial

News

TG Therapeutics’ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising response rates in patients with relapsed or refractory follicular lymphoma, according to new data from a Phase ... Read more

November 7, 2019November 7, 2019

First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy

News

Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse ... Read more

November 5, 2019

Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple ... Read more

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data ... Read more

October 31, 2019

Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma

News

A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people ... Read more

October 29, 2019

Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest

News

Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small ... Read more

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or ... Read more

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial ... Read more